{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:07:57Z","timestamp":1777921677308,"version":"3.51.4"},"reference-count":89,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Melanoma recurrence risk is highest within the first 2 years after diagnosis and progressively declines thereafter. Current surveillance strategies remain largely guided by clinicopathologic risk stratification, with the comprehensive medical history, physical examination, and complete skin assessment forming the cornerstone of follow-up. Although cross-sectional imaging and lymph node ultrasound are used in selected higher-risk patients, routine intensive imaging has not consistently demonstrated survival benefit and may increase costs and false-positive findings. Emerging technologies are reshaping melanoma surveillance and clinical management. Circulating tumor DNA (ctDNA) has shown promise as a minimally invasive biomarker capable of detecting molecular residual disease and anticipating clinical recurrence. Persistent or newly positive ctDNA after surgery is consistently associated with inferior recurrence-free survival. However, ctDNA does not reliably detect all recurrence patterns and its sensitivity varies according to disease burden and metastatic site. Prospective validation and clarification of how ctDNA should guide adjuvant therapy or imaging strategies remain necessary. In parallel, CD8-targeted positron emission tomography (CD8 PET) has emerged as a novel functional imaging modality capable of noninvasively visualizing whole-body T-cell dynamics. By differentiating tumor burden from immune infiltration and capturing early T-cell recruitment, CD8 PET offers predictive insights into immunotherapy response. Nevertheless, limitations of this technique include dependence on optimal imaging timing, limited tracer availability, cost, and an inability to directly assess T-cell functionality. Together, ctDNA and immune-focused imaging approaches represent promising steps toward precision surveillance and management of melanoma. Further robust prospective studies are required to define their integration into clinical decision making and optimize patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/edbk-26-520544","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:59:14Z","timestamp":1777665554000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond Routine Surveillance Imaging for Melanoma: Emerging Technologies for Detecting Early Recurrence and Guiding Clinical Management"],"prefix":"10.1200","volume":"46","author":[{"given":"Giselle","family":"de Souza Carvalho","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Rede Am\u00e9ricas, Rio de Janeiro, RJ, Brazil"},{"name":"Instituto de Pesquisa, Rede Am\u00e9ricas, Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cicero Luiz","family":"Cunha de Sousa Martins","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rede Am\u00e9ricas, Rio de Janeiro, RJ, Brazil"},{"name":"Instituto de Pesquisa, Rede Am\u00e9ricas, Rio de Janeiro, RJ, Brazil"},{"name":"Instituto nacional de Cancer, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Wang","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Farwell","sequence":"additional","affiliation":[{"name":"Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-5374","authenticated-orcid":true,"given":"April K.S.","family":"Salama","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-22539-5_4"},{"key":"e_1_3_2_3_2","unstructured":"International Agency for Research on Cancer: Global Cancer Observatory. 2022. https:\/\/gco.iarc.who.int\/en"},{"key":"e_1_3_2_4_2","volume-title":"Skin Cancer\u2013IARC","author":"WHO","year":"2022","unstructured":"WHO: Skin Cancer\u2013IARC. 2022. https:\/\/www.iarc.who.int\/cancer-type\/skin-cancer\/"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0160"},{"key":"e_1_3_2_6_2","volume-title":"Referenced With Permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Melanoma V.1.2026","unstructured":"Referenced With Permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Melanoma V.1.2026. National Comprehensive Cancer Network. https:\/\/www.nccn.org"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115152"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.006"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00202"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00321-4"},{"key":"e_1_3_2_12_2","article-title":"31-gene expression profile testing in cutaneous melanoma and survival outcomes in a population-based analysis: A SEER collaboration","author":"Bailey CN","unstructured":"Bailey CN, Martin BJ, Petkov VI, et al: 31-gene expression profile testing in cutaneous melanoma and survival outcomes in a population-based analysis: A SEER collaboration. JCO Precis Oncol 10.1200\/PO.23.00044","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.02.1229"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2024.41037"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.4704"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.07.051"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2021.4054"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/12034754231188434"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16833"},{"key":"e_1_3_2_20_2","first-page":"204","article-title":"Serum levels of S-100b protein after four years follow-up of patients with melanoma [in Modern Greek]","volume":"9","author":"Zissimopoulos A","year":"2006","unstructured":"Zissimopoulos A, Karpouzis A, Karaitianos I, et al: Serum levels of S-100b protein after four years follow-up of patients with melanoma [in Modern Greek]. Hell J Nucl Med 9:204-207, 2006","journal-title":"Hell J Nucl Med"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.772165"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14064"},{"key":"e_1_3_2_23_2","volume-title":"Melanoma: Assessment and Management. NICE Guideline NG14\u2014Full Guideline","author":"NICE","year":"2022","unstructured":"NICE: Melanoma: Assessment and Management. NICE Guideline NG14\u2014Full Guideline, 2022. www.nice.org.uk\/guidance\/ng14"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.452"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.018"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07825-7"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005621"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth898"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/941921"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000000233"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07311-0"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-11231-3"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00487-5"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00012"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01222-w"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_351153"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0328-8"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706174"},{"key":"e_1_3_2_39_2","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon SA","year":"1977","unstructured":"Leon SA, Shapiro B, Sklaroff DM, et al: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646-650, 1977","journal-title":"Cancer Res"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3066"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1159\/000226740"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2017.06.004"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1789"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007094"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac202028g"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389202915666150511205313"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.80"},{"key":"e_1_3_2_48_2","article-title":"Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanoma","author":"Varaljai R","unstructured":"Varaljai R, Wistuba-Hamprecht K, Seremet T, et al: Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanoma. JCO Precis Oncol 10.1200\/PO.18.00229","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102914"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504966"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114327"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02583-2"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02355"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404139"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21596"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010141"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17194-z"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000892"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3643"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz048"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00139-1"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx717"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1428541"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2013.09.015"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.229781"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02084-8"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000006098"},{"key":"e_1_3_2_69_2","article-title":"Evaluation of whole body CD8+ T cell distribution using an 18F-labeled PET tracer: Phase 1 studies in patients with solid tumors and healthy volunteers","volume":"13","author":"Wangerin KA","year":"2025","unstructured":"Wangerin KA, Raiter Y, Brouwers AH, et al: Evaluation of whole body CD8+ T cell distribution using an 18F-labeled PET tracer: Phase 1 studies in patients with solid tumors and healthy volunteers. J ImmunoTherapy Cancer 13, 2025 (suppl 2; abstr 104)","journal-title":"J ImmunoTherapy Cancer"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1316922111"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-016-0144-5"},{"key":"e_1_3_2_72_2","first-page":"720","article-title":"CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: A phase I first-in-humans study of 89Zr-Df-IAB22M2C, a radiolabeled Anti-CD8 minibody","volume":"63","author":"Farwell MD","year":"2022","unstructured":"Farwell MD, Gamache RF, Babazada H, et al: CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: A phase I first-in-humans study of 89Zr-Df-IAB22M2C, a radiolabeled Anti-CD8 minibody. J Nucl Med 63:720-726, 2022","journal-title":"J Nucl Med"},{"key":"e_1_3_2_73_2","article-title":"Assessing the correlation between CD8 cell PET imaging with 89-Zr-Crefmirlimab berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy","volume":"10","author":"Postow M","year":"2022","unstructured":"Postow M, Mauguen A, Farwell M, et al: Assessing the correlation between CD8 cell PET imaging with 89-Zr-Crefmirlimab berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy. J ImmunoTherapy Cancer 10, 2022 (suppl 2; abstr 1472)","journal-title":"J ImmunoTherapy Cancer"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4551"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.375"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66767-9"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3098"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0522-3"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0357-y"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno.79976"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269313"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1229620"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53197-2"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-024-06494-x"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268068"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07131-y"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2390"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268289"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-520544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:59:22Z","timestamp":1777665562000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-520544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-520544"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-520544","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e520544"}}